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Introduction
Pulmonary complications occur in 40–60% of bone
marrow transplantation (BMT) recipients, accounting
for 10–40% of all transplant-related deaths.1 Pulmonary
function testing following BMT is useful for predict-
ing survival.2 Indeed, several reports have noted that
small airway obstruction with decreased forced expi-
ratory volume in 1 second (FEV1) and FEV1/forced
vital capacity (FVC) ratio is associated with increased
mortality in patients who have received allogeneic
BMT.1
Airflow obstruction has also been correlated with the
occurrence of chronic graft-versus-host disease (GVHD)
following BMT.3–5 Decrease in diffusion capacity of car-
bon monoxide (DLCO) after BMT has been observed
in chronic myelogenous leukemia patients.6,7 The mech-
anisms underlying this deterioration remain unclear.
The majority of studies assessing the relationship be-
tween pulmonary function and long-term survival fol-
lowing BMT have involved non-homogeneous study
populations. To our knowledge, a homogeneous acute
lymphoblastic leukemia (ALL) population has not been
examined in this manner. Therefore, the aim of this study
was to determine whether changes in FEV1, DLCO,
and the occurrence of chronic GVHD have any long-
term prognostic significance in patients with ALL after
allogeneic BMT.
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Methods
Patient population
The case records of 55 ALL patients who received
allogeneic BMT between August 1983 and February
2005 at our bone marrow unit were retrospectively
reviewed. Our investigation was limited to long-term
survivors only (defined as surviving for at least 100 days
after BMT).1 Hence, 16 patients who died before 100
days post transplantation and 7 who accepted trans-
plantation before complete remission were excluded.
The remaining 32 patients were analyzed.
Twenty-eight patients in the study population ac-
cepted induction chemotherapy with OPDL regimen8
(every 4 weeks with vincristine 1.3 mg/m2 on day 1,
danuomycin 50 mg/m2 qd on day 1–3, prednisolone
40 mg/m2 qd till remission) followed by consolidation
with cytarabine 1,000 mg/m2 q12h on day 1–4 and
novantrone 6mg/m2 qd on day 1–4. Four patients with
ALL accepted the hyper-CVAD regimen (cyclophos-
phamide 300 mg/m2 bid on day 1–3, vincristine 2 mg
on day 4 and day 11, doxorubicin 50 mg/m2 on day 4,
dexamethasone 40 mg on day 1–4 and day 11–14 dur-
ing courses 1, 3, 5 and 7, and methotrexate 1,000 mg/
m2 on day 1, cytarabine 3,000 mg/m2 bid on day 2,
day 3 during courses 2, 4, 6 and 8). Intrathecal CNS
prophylaxis was performed for 6–8 courses with metho-
trexate 15 mg, cytarabine 45 mg, and decadron 5 mg
in each cycle to all patients according to the situation.
BMT procedure
The treatment regimen included conditioning therapy,
GVHD prophylaxis, protective isolation, antibiotics,
and supportive care. Patients entered isolation units
before initiation of conditioning. The conditioning reg-
imen consisted of total body irradiation (TBI) 150 cGy
twice daily for 4 days (total dose 1,200 cGy), with iso-
lating transporter to the radiation room, intravenous
cyclophosphamide 60 mg/kg once daily on days 1 and
2 (total dose 120 mg/kg), and intravenous mesna
20 mg/kg 7 times daily (total dose 140 mg/kg) fol-
lowing the cyclophosphamide course. Non-TBI con-
ditioning was as follows: busulfan 4 mg/kg per os in
divided doses daily for 4 days (total dose 16 mg/kg),
cyclophosphamide 50 mg/kg daily for 4 days (total
dose 200mg/kg), intravenous mesna 20mg/kg 7 times
daily (total dose 140 mg/kg). Most patients received
a combination of radiation therapy and chemotherapy.
Patients not allergic to sulfamethoxazole and trimetho-
prim received prophylactic treatment for 2 weeks before
transplantation and from the time of primary dis-
charge after transplantation for at least 6 months, or
until peripheral white blood cell counts normalized.2
Cytomegalovirus (CMV) infection was monitored
with CMV-PCR weekly post transplant until 100 days
after the day of transfusion. Diagnosis of CMV colitis
was confirmed by histologic examination of colonos-
copy biopsy specimens. Diagnosis of CMV pneumonitis
was confirmed by histologic examination of pulmonary
macrophages obtained by broncholavage.
GVHD prophylaxis, grading and treatment
All patients received the following GVHD prophylaxis:
intravenous cyclosporin A 5 mg/kg or 6.25 mg/kg
per os from day −1 to day +60; intravenous methotrex-
ate 15 mg/m2 on day +1, and 10 mg/m2 on days +3,
+6 and +11. Acute GVHD was graded according to
published criteria.9 Chronic GVHD was classified as
described by Schulman and colleagues.10
Acute GVHD was treated with prednisolone 2 mg/
kg daily and cyclosporin 6.25 mg/kg daily, adjusted
with methylprednisolone at a dose of 20 mg/kg/day
for 3–5 days and ATG 30 mg/kg every other day for
6 doses. These doses were increased if improvements
were not apparent.
Pulmonary function tests
Pulmonary function tests were performed before, and
every 3 months after BMT according to American
Thoracic Society guidelines. Measurements were made
using the following equipment: between 1983 and
1993, a wet-spirometer (model 750; Med Science
Electronics, St Louis, MO, USA) combined with an XY
recorder (Hewlett-Packard, Palo Alto, CA, USA) and a
1-second timer; between March 1993 and November
2003, a Sensormedics Autobox 6200 (Sensormedics
Co., Yorba Linda, CA, USA); and from December
2003 onwards, a Sensormedics Vmax (Sensormedics
Co.). Previously published equations were used to deter-
mine predicted FEV1 values.11 DLCO was measured
using the single-breath technique and corrected for
hemoglobin content. Obstruction was categorized as
mild (≥ 70% FEV1), moderate (60–69% FEV1), mod-
erately severe (50–59% FEV1), severe (35–49% FEV1),
or very severe (< 35%). Diffusion capacity was catego-
rized as pathological (DLCO<80% of predicted value),
mild (60–80% of predicted value), moderate (40–59%
of predicted value), or severe (DLCO < 40% of pre-
dicted value) according to European Respiratory Society
guidelines. Decreases in FEV1 or DLCO were defined
according to the grading systems of the American
Thoracic and European Respiratory Societies (ATS/
ERS),12 and were indicated by an increase of at least 1
severity grade between pre-BMT and 12 months post-
BMT (e.g. a shift from mild to moderate, moderate
to severe, etc.).
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Statistical methods
Overall and event-free survivals were defined as the
intervals between diagnosis and death, and between
complete remission and disease recurrence, respectively.
The Kaplan-Meier method was used to estimate over-
all survival and event-free survival. Log-rank tests were
performed to assess any association between survival
and risk factors. A Cox proportional hazard model was
then applied to identify prognostic factors that signif-
icantly influenced overall survival and event-free sur-
vival. All analyses were performed using the SAS 9.01
statistical software package (SAS Institute Inc., Cary,
NC, USA). A p value of less than 0.05 was considered
to indicate significance.
Results
Patient characteristics and clinical features
The demographic and clinical characteristics of the 32
ALL patients who survived at least 100 days after allo-
geneic BMT are presented in Table 1.
Pulmonary function, chronic GVHD, and
prognosis
The univariate analysis results for overall and event-
free survival prognostic factors are presented in Table 2.
Both decreased DLCO and a pre-BMT FEV1 < 70%
significantly influenced overall survival (both p < 0.05).
Overall survival was significantly higher in patients with
decreased DLCO. Mortality risk was almost 5 times
higher when pre-BMT FEV1 was <70% of the predicted
value. Neither a decreased FEV1 score post-BMT, nor
development of either acute or chronic GVHD influ-
enced overall survival (all p > 0.05). Decreased DLCO
after BMT was associated with significantly improved
event-free survival (p<0.05). There were only 6 patients
in whom FEV1 decreased following BMT (relapse was
not apparent in any of these individuals); hence, we
were unable to establish an association using the Cox
proportional model.
Considering the predisposing factors that may influ-
ence prognosis, although no apparent significance in
univariate analysis was observed in the present study,
these factors were enrolled into the multivariate analy-
sis. Multivariate analysis (Table 3) revealed that lim-
ited chronic GVHD was associated with a significantly
decreased risk of death (HR, 0.14; p<0.05), while CMV
infection significantly increased risk of death (HR,
21.91; p<0.05). After adjusting for age, gender, chronic
GVHD and CMV infection status, decreased DLCO
was significantly predictive for both increased overall
survival and event-free survival (p < 0.05).
Table 1. Characteristics of 32 acute lymphoblastic leukemia
patients who survived at least 100 days after allogeneic bone
marrow transplantation (BMT)*
Age at BMT 25 (11.5–50.6)
Adult (> 18 yr)
No 7 (21.87)
Yes 25 (78.13)
Gender
Female 15 (46.9)
Male 17 (53.1)
Months to CR1 after diagnosis 1.30 (0.7–5.5)
Months to BMT after diagnosis 6.73 (3.60–44.00)
Overall survival (mo) 43.22 (11.00–173.43)
Event-free survival (mo) 33.62 (7.97–173.43)
Disease status at BMT
CR1 29 (90.62)
CR2 3 (9.38)
CMV infection
No 27 (84.37)
Yes 5 (15.63)
Philadelphia chromosome
Positive 5 (15.63)
Negative 27 (84.37)
Smoking
No 26 (81.25)
Yes 6 (18.75)
Conditioning regimen
BU + CY 3 (9.38)
TBI + CY 29 (90.62)
Acute GVHD
No 24 (75.00)
Grade 1 3 (9.38)
Grade 2 4 (12.50)
Grade 3 1 (3.13)
Chronic GVHD
No 13 (40.63)
Limited 11 (34.38)
Extensive 8 (25.00)
Pre-BMT FEV1 grade
Mild (≥ 70%) 29 (90.63)
Moderate (60–70%) 2 (6.25)
Moderately severe (50–60%) 1 (3.13)
FEV1 decreased following BMT
No 26 (81.25)
Yes 6 (18.75)
Pre-BMT DLCO grade
Mild (80–60%) 6 (18.75)
Moderate (40–60%) 18 (56.25)
Severe (< 40%) 8 (25.00)
DLCO decreased following BMT
No 17 (53.13)
Yes 15 (46.88)
*Data presented as median (range) or n (%). CR1 = first complete remission;
CR2 = second complete remission; CMV = cytomegalovirus; BU = busulfan;
CY = cyclophosphamide; TBI = total body irradiation; GVHD = graft-versus-host
disease; FEV1 = forced expiratory volume in 1 second; DLCO = diffusion capacity
for carbon monoxide.
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Figure 1 shows the Kaplan-Meier overall and event-
free survival curves for patients in whom DLCO did
or did not decrease following BMT. The 2-year sur-
vival rates were 93% and 64% for patients who did and
did not exhibit decreased DLCO scores, respectively.
Corresponding 2-year event-free survival rates were
93% and 53%. Both the differences for overall and
event-free survivals between the groups were signifi-
cant (p < 0.05).
Discussion
This study primarily assessed measures of pulmonary
function as indicators of long-term outcome in patients
with ALL following BMT. Our findings suggest that
post-BMT DLCO may be such a prognostic factor.
Previous studies have reported that DLCO de-
creases are apparent in up to 80% of all BMT sur-
vivors, including those in good health.13–18 Further
Table 2. Univariate analysis results for overall and event-free survival risk factors in 32 acute lymphoblastic leukemia patients after
allogeneic bone marrow transplantation (BMT)
Overall survival Event-free survival
HR 95% CI p* HR 95% CI p*
Age 1.01 (0.96–1.07) 0.72 1.00 (0.94–1.06) 0.98
Sex
Female – –
Male 0.75 (0.24–2.33) 0.61 1.22 (0.29–5.10) 0.79
Smoking
No – –
Yes 0.25 (0.03–2.00) 0.19 0.56 (0.07–4.58) 0.59
Months to BMT after diagnosis 1.01 (0.96–1.06) 0.77 1.01 (0.94–1.09) 0.77
Conditioning regimen
BU + CY – –
TBI + CY 1.77 (0.21–15.29) 0.60 0.73 (0.09–5.96) 0.77
HLA matching
Siblings – –
MUD 0.85 (0.23–3.17) 0.80 1.04 (0.25–4.37) 0.95
CMV infection
No – –
Yes 1.93 (0.41–9.12) 0.41 0.81 (0.10–6.64) 0.85
Acute GVHD
No – –
Yes 0.77 (0.17–3.56) 0.74 0.46 (0.06–3.74) 0.47
Chronic GVHD
None – –
Limited 1.30 (0.38–4.51) 0.68 0.38 (0.04–3.42) 0.39
Extensive 0.30 (0.06–1.56) 0.15 0.82 (0.18–3.68) 0.79
Pre-BMT FEV1 < 70%
No – –
Yes 4.79 (1.19–19.29) 0.03† 3.26 (0.65–16.29) 0.15
FEV1 decreased after BMT
No – –
Yes 1.21 (0.33–4.49) 0.77 – – –
DLCO decreased after BMT
No – –
Yes 0.17 (0.04–0.79) 0.02† 0.11 (0.01–0.90) 0.04†
*p value as determined by Cox proportional hazard regression analyses; †a significant risk factor. HR = hazard ratio; CI = confidence interval; BU = busulfan;
CY = cyclophosphamide; TBI = total body irradiation; HLA = human leukocyte antigen; MUD = matched unrelated donor; CMV = cytomegalovirus; GVHD = graft-
versus-host disease; FEV1 = forced expiratory volume in 1 second; DLCO = diffusion capacity for carbon monoxide.
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to this, it is indicated that DLCO decreases occur
within the first 3 months post BMT and that sub-
sequent recovery is incomplete.2,19–23 Such persistent
decreases in DLCO may be reflective of permanent
damage to the alveolar–endothelial membrane and sub-
clinical pulmonary fibrosis.6,24,25 In the current study,
we also found that decreased DLCO 1 year after BMT
was associated with enhanced survival rate. A number
of previous studies have failed to find such an associ-
ation between decreased DLCO and mortality.2,5,6,26
The mechanism(s) underlying the apparent positive
influence of decreased DLCO on survival in this study
are unclear. Similar interesting findings were observed
in a previous study.27 In Philadelphia chromosome pos-
itive (Ph+) ALL patients after allogeneic stem cell
transplantation, those with chronic GVHD had better
survival compared to those without chronic GVHD.
Although the true mechanism of such a clinical find-
ing is unclear, there may be some correlation between
chronic GVHD, enhanced graft-versus-leukemia (GVL)
Table 3. Multivariate analysis for prognostic factors affecting overall and disease-free survival in 32 acute lymphoblastic leukemia
patients after allogeneic hematopoietic stem cell transplantation
Overall survival Event-free survival
HR 95% CI p* HR 95% CI p*
Age 1.01 (0.95–1.07) 0.81 0.98 (0.92–1.06) 0.66
Gender
Female – –
Male 1.09 (0.31–3.81) 0.90 1.75 (0.34–9.01) 0.50
Chronic GVHD
None – –
Limited 0.14 (0.02–0.90) 0.04† 0.57 (0.10–3.21) 0.52
Extensive 0.45 (0.11–1.85) 0.27 0.14 (0.01–1.59) 0.11
DLCO decreased after BMT
No – –
Yes 0.05 (0.01–0.43) 0.01† 0.07 (0.01–0.60) 0.02†
CMV infection
No – –
Yes 21.91 (1.76–273.12) 0.02† 2.12 (0.20–22.34) 0.53
*p value as determined by Cox proportional hazard regression analyses; †a significant risk factor. HR = hazard ratio; CI = confidence interval; GVHD = graft-
versus-host disease; DLCO = diffusion capacity for carbon monoxide; BMT = bone marrow transplantation; CMV = cytomegalovirus.
Figure 1. Kaplan-Meier survival curves for acute lymphoblastic leukemia patients in whom diffusion capacity for carbon monoxide
(DLCO) did or did not decrease following allogeneic bone marrow transplantation: (A) event-free survival; (B) overall survival.
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effect and decreased DLCO in ALL patients, which
warrants further investigation.
Several reports have noted an association between
diminished FEV1 due to small airway obstruction and
concomitant chronic GVHD and increased frequency
of late non-relapse death.5,26 We did not find any such
associations in the present study. However, as already
noted, there was an insufficient number of patients who
experienced post-BMT decreases in FEV1 to allow for
definitive analysis. We did find that pre-BMT FEV1
< 70% was associated with an increased mortality risk.
There have been reports indicating that there is an
association between abnormal FEV1 values and an
increased risk of treatment-related mortality and post-
transplantation CMV infection.28
A number of studies have indicated that chronic
GVHD is a highly significant risk factor for the devel-
opment of airflow obstruction following BMT.29,30
Similarly, others have noted that chronic GVHD is a risk
factor for airflow obstruction and increased non-relapse
mortality and morbidity after allogeneic BMT.4,18,31
In the current investigation, we found that patients
who experienced limited chronic GVHD following
allogeneic BMT had better overall survival as compared
to patients who did not have GVHD. Yanada and col-
leagues found that extensive chronic GVHD was asso-
ciated with increased survival in ALL patients who
received allogeneic BMT.27 The positive impact of lim-
ited chronic GVHD on survival might be explained
by an associated GVL effect.27,32
Crawford and colleagues have previously presented
findings demonstrating that decreased DLCO before
transplantation is an independent factor for increased
risk of death after BMT.2,33 We did not find this to be
the case in the present study. Our finding is in keeping
with that of Ghalie et al, who also found no associa-
tion between pre-transplant DLCO and post-transplant
pulmonary complications or outcome.34 CMV infection
was correlated with mortality in our study. This may be
related to the high mortality rate of documented CMV
infection and poorer general condition and immunity
of the patients who got CMV infections.
There are a number of limitations to our study. Due
to the relatively small sample size, associations between
decreased FEV1, decreased DLCO, and chronic GVHD
could not be determined. Thus, we cannot exclude
the possibility that the effects of decreased DLCO
and chronic GVHD may overlap. Also related to the
small sample size, we were not able to assess the effect
of decreased DLCO on more long-term survival (i.e.
> 1 year). Another shortcoming is that because the data
pertaining to total lung capacity were incomplete and
could not be analyzed, its significance as a risk factor
could not be evaluated. Previous reports have noted
reduced total lung capacity to be associated with an
increase in non-relapse mortality following BMT.2,18
Studies with larger patient groups and/or animal models
are warranted to address these unresolved issues.
To our knowledge, this is the first study to exam-
ine the relationship between long-term survival and
pulmonary function changes in ALL patients after allo-
geneic BMT. We found that decreased DLCO follow-
ing allogeneic BMT was associated with better survival
in these patients. The relationship between DLCO
decrease, chronic GVHD and the GVL effect needs
to be further studied. Additional research utilizing the
ATS/ERS grading system to separate positive and
negative GVL patients may provide further insight.
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